AI PRICE FORECAST
ABBV Stock Forecast & AI Price Prediction
AbbVie · Healthcare · Drug Manufacturers - General
ABBV live signal snapshot
Shares of ABBV were last at $294.98, up 0.37% on the day, trading within 2.6% of its 52-week high of $302.93. The model's verdict for ABBV right now: BUY (87% confidence). The short-term averages line up bullishly, and the price is holding above its 50-day line. Its one-month projection is about $305.36, a 3.5% move from the last price.
ABBV's 14-day RSI is 61.2 — healthy bullish momentum without being overextended. The MACD indicator trails its signal line, with a histogram of -0.23 pointing to selling pressure. The 50-day moving average ($274.15) sits 14.2% above the 200-day ($240.04) — a "golden cross" structure that typically supports the longer-term uptrend.
26 Wall Street analysts covering ABBV put the average price target at $310.65 (range $237.00–$350.00), implying 5.3% upside from the current price. The current recommendation trend leans bullish: 23 Buy/Strong Buy ratings vs 1 Sell/Strong Sell (and 5 Hold).
Live figures from real market data feeds, current as of the last site build. Open the interactive ABBV dashboard for numbers updated throughout today's session.
About AbbVie
AbbVie Inc. (ABBV) is a drug manufacturers - general company in the healthcare sector, headquartered in North Chicago, IL, United States. AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. It has a market value of about $521.4 billion and roughly 57,000 full-time employees. With a beta of 0.19, the stock has historically moved less than the overall market.
ABBV performance vs. the market
Since the start of 2026 the stock has risen 29.1%, ahead of the S&P 500 (+11.4%) and ahead of the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has gained 34.9%, 23.4 points better than the S&P 500. Its +7.5% move over the past month extends a +17.6% three-month run.
| Period | ABBV | Sector (XLV) | S&P 500 |
|---|---|---|---|
| 1 month | +7.5% | +11.4% | −2.3% |
| 3 months | +17.6% | +12.2% | −2.3% |
| Year to date | +29.1% | +22.1% | +11.4% |
| 1 year | +34.9% | +28.3% | +11.5% |
AbbVie financials at a glance
AbbVie's most recent quarter (ended Sep 30, 2026) brought in $17.4 billion of revenue and net income of $4.2 billion (a 24.2% net margin). Revenue was up 10.3% from the same quarter a year earlier. The stock trades at a price-to-earnings ratio of 50.7 on trailing earnings of $5.82 per share. Trailing free cash flow was $17.7 billion.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Sep 30, 2026 | $17.4B | $4.2B |
| Jun 30, 2026 | $17.0B | $3.6B |
| Mar 31, 2026 | $15.0B | $695M |
| Dec 31, 2025 | $16.6B | $1.8B |
ABBV vs. its peers
ABBV's +29.1% this year ranks ahead of 0 of the 5 big healthcare names below. The strongest of the group this year is Amgen (AMGN, +43.0%).
| Company | Price | YTD | P/E | AI verdict |
|---|---|---|---|---|
| AbbVie (ABBV) | $294.98 | +29.1% | 50.7 | BUY |
| Eli Lilly and (LLY) | $1,437.29 | +33.7% | 46.7 | BUY |
| Johnson & Johnson (JNJ) | $280.41 | +35.5% | 42.6 | BUY |
| Merck & Co. (MRK) | $147.18 | +39.8% | 148.7 | HOLD |
| Amgen (AMGN) | $468.11 | +43.0% | 27.1 | BUY |
| Gilead Sciences (GILD) | $169.73 | +38.3% | — | BUY |
ABBV stock: common questions
What is the ABBV stock price target?
26 Wall Street analysts put the average 12-month target at $310.65, in a range of $237.00–$350.00, versus a recent price of $294.98. Stock Pulse 247's model projects about $305.36 over the next month.
Is ABBV a buy right now?
Our AI model currently rates ABBV a BUY at 87% confidence. Among analysts, 23 rate it Buy or Strong Buy, 5 Hold and 1 Sell. Neither is personal advice — weigh them with your own research and risk tolerance.
How has ABBV stock performed this year?
Since the start of 2026 the stock has risen 29.1%, ahead of the S&P 500 (+11.4%) and ahead of the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has gained 34.9%, 23.4 points better than the S&P 500. Its +7.5% move over the past month extends a +17.6% three-month run.
What is ABBV's 52-week high and low?
ABBV has traded between $190.75 and $302.93 over the past 52 weeks; at $294.98 it is within 2.6% of its 52-week high of $302.93.
What sector is ABBV in, and who are its peers?
ABBV is in the healthcare sector (drug manufacturers - general). Its largest peers on Stock Pulse 247 include Eli Lilly and (LLY), Johnson & Johnson (JNJ), Merck & Co. (MRK), Amgen (AMGN).
How accurate is the ABBV forecast?
It's a model estimate from price history, technical indicators and analyst targets, not a guarantee — no model predicts short-term moves reliably. Use it as one input alongside your own research.
How this works: the forecast combines ABBV's price history, momentum indicators (RSI, MACD, moving averages), volatility and analyst targets into one estimate. It's a model, not a guarantee.